Vigilex Xendo DeutschlandXendo Deutschland

Welcome to the Xendo website

Xendo is a leading, independent consultancy and project management organization in the life sciences, pharmaceutical and healthcare fields. Our ambition is to enhance the quality and safety of medicine and help shorten the time to market for drugs and medical devices that improve the quality of life.

For over 25 years we have supported hundreds of clients in more than 25 countries worldwide. For further information please contact us at info@xendo.com. Or just click one of the buttons to find out what Xendo can do in your area of expertise.

 

Pharmacovigilance Argus

Oracle Argus is regarded as the ‘golden standard’ pharmacovigilance safety database. By applying a multi-tenant approach and by using the Argus workflow manager we have lean processes and are able to offer this software as a cost-effective solution. With this state-of-the-art database, reports for case processing can be generated independent of the size of a corporation. With the Argus Safety Database, Xendo offers the same scope of activities to small and mid-sized biotech, pharmaceutical and medical device companies looking for an AEM solution.

Read more

News

Xendo awarded for the second year in a row as FD Gazelle

Xendo was named an FD Gazelle 2016, meaning it belongs to the fastest growing companies in the Netherlands again. The Gazelle Awards, an initiative of the ‘Financieele Dagblad’ (Dutch Financial Times), are awarded annually to the fastest growing enterprises, where the main criterion is a turnover growth of at least 20% per year during a three-year period.

André van de Sande (CEO, Xendo) says: We have realised excellent growth over the past years and we have grown from 60 to over 150 employees. This is the second year we have been awarded a Gazelle, meaning we are showing robust growth of our company. Although we are operating in a competitive market, our clients increasingly know how to find us and we would like to thank them for the trust they place in Xendo.

 

 

 

Latest blog: